Advair Hfa Aerosol, Metered
Product Images NDC 50090-3672

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Advair Hfa (NDC 50090-3672). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Chemical Structure (Advairhfa Spl Graphic 01)

Chemical structure diagram of the active ingredient fluticasone propionate from the ADVAIR HFA prescription aerosol inhalation product.*

FDA Label Image

Salmeterol Chemical Structure (Advairhfa Spl Graphic 02)

Chemical structure diagram of fluticasone propionate and salmeterol xinafoate, the active ingredients in ADVAIR HFA.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects Previously Treated With Either Beta2 Agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 03)

A line graph showing percent change in FEV1 over 12 weeks for four groups: ADVAIR HFA 45 mcg/21 mcg (two inhalations twice daily), fluticasone propionate inhalation aerosol 44 mcg (two inhalations twice daily), salmeterol inhalation aerosol 21 mcg (two inhalations twice daily), and placebo. ADVAIR HFA shows the highest increase, with data points across weeks and subject counts listed below the x-axis.*

FDA Label Image

Figure 2. Mean Percent Change From Baseline In Morning Peak Expiratory Flow In Subjects Previously Treated With Inhaled Corticosteroids (trial 4) (Advairhfa Spl Graphic 04)

A line chart depicting the percentage change in AM PEF over 12 weeks for three treatments: ADVAIR HFA 230 mcg/21 mcg (2 inhalations twice daily), ADVAIR DISKUS 500 mcg/50 mcg (1 inhalation twice daily), and fluticasone propionate inhalation aerosol 220 mcg (2 inhalations twice daily). The chart includes participant counts at several time points for each treatment group.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 05)

Line graph showing the percentage change in FEV1 over 12 hours from baseline (Day 1) comparing ADVAIR HFA 45 mcg/21 mcg (two inhalations twice daily), fluticasone propionate inhalation aerosol 44 mcg (two inhalations twice daily), salmeterol inhalation aerosol 21 mcg (two inhalations twice daily), and placebo. ADVAIR HFA shows the highest increase, followed by salmeterol, fluticasone propionate, and placebo.*

FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Subjects Previously Using Either Beta2-agonists (albuterol Or Salmeterol) Or Inhaled Corticosteroids (trial 1) (Advairhfa Spl Graphic 06)

A line graph showing percentage change in FEV1 relative to Day 1 baseline over 12 hours for various treatments including ADVAIR HFA 45 mcg/21 mcg, fluticasone propionate inhalation aerosol 44 mcg, salmeterol inhalation aerosol 21 mcg, and placebo. The graph compares treatment effects after Day 1 and at Week 12, with FEV1 percentage change on the vertical axis and time in hours on the horizontal axis.*

FDA Label Image

Figure A (Advairhfa Spl Graphic 07)

An illustration diagram of an ADVAIR HFA metered-dose inhaler showing labeled parts including the metal canister, purple plastic actuator, purple mouthpiece, counter, and a separate light purple cap.*

FDA Label Image

Figure B (Advairhfa Spl Graphic 08)

An instructional illustration showing two hands: one holding an inhaler and the other holding a protective cap. An arrow indicates the action of removing the cap from the inhaler, demonstrating proper preparation for use.*

FDA Label Image

Figure C (Advairhfa Spl Graphic 09)

An instructional illustration showing the use of an ADVAIR HFA inhaler, a respiratory aerosol metered dose device. The image depicts a person pressing down on the inhaler top to release a sprayed dose, with the device held upright and mouth near the mouthpiece. A cap is shown removed and placed nearby.*

FDA Label Image

Figure D (Advairhfa Spl Graphic 10)

An illustration showing a hand holding and pressing down on the top of an inhaler device labeled with the number 120, indicating the number of doses. This demonstrates the use of the inhaler for respiratory medication delivery.*

FDA Label Image

Figure E (Advairhfa Spl Graphic 11)

Illustration showing the proper 'Mouthpiece-Down position' for using an inhaler. The image identifies the purple mouthpiece and the light purple cap, demonstrating how the device should be held during use.*

FDA Label Image

Figure F (Advairhfa Spl Graphic 12)

An instructional illustration showing a side profile of a person's face with an arrow indicating exhalation from the mouth. Text reads 'Breathe out as much air as you can,' depicting a step likely related to the use of a respiratory inhalation aerosol device.*

FDA Label Image

Figure G (Advairhfa Spl Graphic 13)

An instructional illustration showing a person using an inhaler. The person is holding the inhaler near their mouth, pressing down on the canister to release medication while inhaling. The image includes the text "Push down and breathe in" with an arrow pointing to the pressed inhaler.*

FDA Label Image

Figure H (Advairhfa Spl Graphic 14)

An instructional illustration showing a person rinsing their mouth over a sink with water, likely demonstrating proper inhaler use or oral hygiene after using an inhalation aerosol.*

FDA Label Image

Figure I (Advairhfa Spl Graphic 15)

Instructional diagram showing two states of an aerosol inhaler: one labeled 'Not blocked' demonstrating proper spray release, and one labeled 'Blocked' showing an obstructed spray with no output. This guides users on correct inhaler use to ensure medication delivery.*

FDA Label Image

Figure J (Advairhfa Spl Graphic 16)

Instructional illustration showing a hand using a swab or tool to clean or handle the mouthpiece section of an inhaler device. The image demonstrates rotating or wiping motion applied to the inhaler mouthpiece.*

FDA Label Image

Label Image (Lbl500903672)

Medication label for ADVAIR HFA 115 mcg/21 mcg metered aerosol inhaler by A-S Medication Solutions. Contains 120 metered actuations with 12 g net weight. Instructions include storing between 68 to 77 degrees Fahrenheit and keeping the inhaler with the mouthpiece down. Distributed by A-S Medication Solutions, Libertyville, IL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.